Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 191 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Hospitalization Clear all
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 16, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs

NCT07419360
View directory record Official record
Conditions
Congestive Heart Failure(CHF), Pleural Effusion Due to Congestive Heart Failure
Interventions
Thoracentesis
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 16, 2026, 5:28 AM EDT
Terminated Not applicable Interventional

AML Expressive Writing

NCT04006496
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Expressive Writing Coaching
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 16, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792
View directory record Official record
Conditions
Steroid Refractory GVHD
Interventions
RLS-0071
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 16, 2026, 5:28 AM EDT
Not yet recruiting Phase 4 Interventional

Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

NCT07502339
View directory record Official record
Conditions
UC - Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

NCT04590586
View directory record Official record
Conditions
COVID-19
Interventions
Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 16, 2026, 5:28 AM EDT
Enrolling by invitation Phase 1 Interventional

Nitrous Oxide- Suicidal Ideation

NCT03736538
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Mood Disorders, Suicidal Ideation
Interventions
Nitrous Oxide, Placebo gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 16, 2026, 5:28 AM EDT
Not listed No phase listed Observational

Interstitial Lung Diseases in the Veterans Administration

NCT02479126
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Robert Tighe
Federal
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Phase 4 Interventional

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

NCT00181818
View directory record Official record
Conditions
Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions
bupropion SR (sustained-release)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Sep 16, 2026, 5:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Human Algorithm Interactions for Acute Respiratory Failure Diagnosis

NCT06098950
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Artificial Intelligence model predictions without explanation, Artificial intelligence model predictions with explanation, AI model biased against heart failure, AI model biased against pneumonia, AI model biased against COPD
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 16, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma

NCT01227070
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Sep 16, 2026, 5:28 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

KIDney Injury in Times of COVID-19 (KIDCOV)

NCT04705766
View directory record Official record
Conditions
SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Interventions
Urine Collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 16, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 16, 2026, 5:28 AM EDT
Not listed No phase listed Observational

Voice Analysis for Monitoring Patients With Heart Failure

NCT06566911
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Noah Labs
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis

NCT01981356
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Acceptance and Commitment Therapy, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 16, 2026, 5:28 AM EDT
Terminated Not applicable Interventional Results available

OPEP Devices in Acute Inpatient Treatment of Pneumonia

NCT04540510
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
OPEP therapy, Standard care
Device · Other
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774
View directory record Official record
Conditions
Covid19
Interventions
theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 16, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 16, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Tolerance and Acute Effects of a New HFNT Nasal Cannula

NCT05182294
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
AIRVO 2, the new asymmetric nasal cannula
Device
Lead sponsor
Temple University
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 16, 2026, 5:28 AM EDT
Not listed Phase 3 Interventional

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

NCT05204368
View directory record Official record
Conditions
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions
Combination of Imipenem/Cilastatin and XNW4107, Meropenem
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 16, 2026, 5:28 AM EDT
Not yet recruiting Not applicable Interventional

Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury

NCT07217808
View directory record Official record
Conditions
Acute Kidney Injury (AKI)
Interventions
PRECISE-AKI Clinical Decision Support Tool
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 16, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 16, 2026, 5:28 AM EDT